
USD
( +0.00%
At Close (As of Jan 1, 1970)
$348.33M
Market Cap
-
P/E Ratio
-1.02
EPS
$3.78
52 Week High
$0.86
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $22K |
| Total Revenue | $22K |
| Cost Of Revenue | $14M |
| Costof Goods And Services Sold | $14M |
| Operating Income | -$273M |
| Selling General And Administrative | $65M |
| Research And Development | $192M |
| Operating Expenses | $273M |
| Investment Income Net | - |
| Net Interest Income | $20M |
| Interest Income | $20M |
| Interest Expense | $181K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $14M |
| Income Before Tax | -$257M |
| Income Tax Expense | $443K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$258M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$257M |
| Ebitda | -$243M |
| Net Income | -$258M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$200M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $14M |
| Capital Expenditures | $694K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $76M |
| Cashflow From Financing | $117M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $1.5M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$258M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $22K |
| Total Revenue | $22K |
| Cost Of Revenue | $14M |
| Costof Goods And Services Sold | $14M |
| Operating Income | -$273M |
| Selling General And Administrative | $65M |
| Research And Development | $192M |
| Operating Expenses | $273M |
| Investment Income Net | - |
| Net Interest Income | $20M |
| Interest Income | $20M |
| Interest Expense | $181K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $14M |
| Income Before Tax | -$257M |
| Income Tax Expense | $443K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$258M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$257M |
| Ebitda | -$243M |
| Net Income | -$258M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Allogene Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of next-generation allogeneic T-cell therapies designed to target various forms of cancer. Leveraging its proprietary technology platform, Allogene aims to deliver transformative immuno-oncology treatments that enhance the body’s natural ability to fight cancer while minimizing associated treatment risks and complexities. With a strong pipeline of candidates and a dedicated focus on advancing therapeutic solutions, Allogene is positioned to significantly impact the oncology landscape.